Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19160278rdf:typepubmed:Citationlld:pubmed
pubmed-article:19160278lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:19160278lifeskim:mentionsumls-concept:C0238598lld:lifeskim
pubmed-article:19160278lifeskim:mentionsumls-concept:C0029463lld:lifeskim
pubmed-article:19160278lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:19160278pubmed:issue1lld:pubmed
pubmed-article:19160278pubmed:dateCreated2009-1-22lld:pubmed
pubmed-article:19160278pubmed:abstractTextThe majority of the currently used treatment protocols for osteosarcoma are based on a combination of doxorubicin, cisplatin, methotrexate (MTX) and/or ifosfamide, of which MTX seems to be one of the most active drugs. However, in the literature, this has not been unambiguously proven.lld:pubmed
pubmed-article:19160278pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19160278pubmed:languageenglld:pubmed
pubmed-article:19160278pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19160278pubmed:citationSubsetIMlld:pubmed
pubmed-article:19160278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19160278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19160278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19160278pubmed:statusMEDLINElld:pubmed
pubmed-article:19160278pubmed:issn1469-493Xlld:pubmed
pubmed-article:19160278pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:19160278pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:19160278pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19160278pubmed:ownerNLMlld:pubmed
pubmed-article:19160278pubmed:authorsCompleteYlld:pubmed
pubmed-article:19160278pubmed:paginationCD006325lld:pubmed
pubmed-article:19160278pubmed:dateRevised2011-6-6lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:meshHeadingpubmed-meshheading:19160278...lld:pubmed
pubmed-article:19160278pubmed:year2009lld:pubmed
pubmed-article:19160278pubmed:articleTitleMethotrexate for high-grade osteosarcoma in children and young adults.lld:pubmed
pubmed-article:19160278pubmed:affiliationPaediatric Oncology, Emma Children's Hospital / Academic Medical Center, PO Box 22660 (room F8-257), Amsterdam, Netherlands, 1100 DD. e.c.vandalen@amc.uva.nllld:pubmed
pubmed-article:19160278pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19160278pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19160278lld:pubmed